Evolución de los efectos físicos y bioquímicos en diabéticos tipo 2 con riesgo cardiovascular y uso de inhibidor de la DPP-4 (linagliptina)

S, Bierwirth R, Fritsche A, Gallwitz B, Häring HU, et al (2009) Medical antihyperglycaemic treatment of type 2 diabetes mellitus: update of the evidence-based guideline of the German Diabetes Association. Exp Clin Endocrinol Diabetes 117: 522–557.

12. Svec F (2010) Incretin physiology and its role in type 2 diabetes mellitus. J Am Osteopath Assoc 110 (7 Suppl 7): eS20-24.

13. Yoon NM, Cavaghan MK, Brunelle RL, Roach P (2009) Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting. Clin Ther 31 (7): 1511-1523.